Calidi Biotherapeutics Narrows Q3 Loss to $3.6 Million
The San Diego biotech reported a third-quarter 2026 net loss after cutting headcount and executing a restructuring plan.
Updated on Nov. 13, 2026 in Corporate Finance
Calidi Biotherapeutics reported a $3.6 million net loss attributable to common stockholders for the third quarter of 2026, down from $10.8 million a year earlier. The San Diego company also executed a restructuring plan on November 6, 2026, predominantly through a headcount reduction.
Why it matters
The restructuring is intended to extend the company's cash runway, reduce costs and preserve capital while it pursues additional financing. Lower operating expenses reduce pressure on a company with limited cash on hand.
Research and development expenses were $2.7 million and general and administrative expenses were $1.6 million in the third quarter of 2026, with cash of $3.9 million as of September 30, 2026. The restructuring is projected to save $3 million annualized, though the extraction does not specify how the savings will be allocated across spending lines.
The players
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics is a clinical-stage biotechnology company based in San Diego, California, developing cell-based therapies for cancer.
The details
Calidi raised $1.2 million in gross proceeds through an at-the-market registered direct offering that closed on September 18, 2026. The company presented two posters at the ESMO Congress 2026 on October 24, 2026, and plans to dose its first patient in the second half of 2027.
Timeline
Year-end 2025: Calidi recorded a $5.6 million cash balance.
September 18, 2026: At-the-market offering closed, generating $1.2 million.
October 24, 2026: Two posters presented at ESMO Congress 2026.
November 6, 2026: Restructuring plan executed, mainly through headcount reduction.
Second half of 2027: First patient dosing planned.
Capital Constraints
Calidi's cost cuts mirror a pattern seen across clinical-stage biotechs since the 2022–2024 venture funding pullback, when many small drug developers reduced headcount to extend runways before raising new money. The company's $3.9 million cash position places it in that same squeeze, with its first patient dosing not expected until the second half of 2027.
Shareholders face ongoing dilution risk because the company raised funds through at-the-market offerings and still needs additional financing. Investors should watch whether the $3 million annualized savings is enough to extend the cash runway until the 2027 patient dosing milestone.
The takeaway
Cost cuts can buy time for a cash-strained biotech, but they do not replace the need for new capital. Readers tracking the company should follow its financing progress alongside its clinical timeline.
Further reading
Explore more corporate finance coverage for San Diego companies.
Source note: This article includes information reported by The Manila times.
